Iota-carrageenan is a potent inhibitor of influenza a virus infection

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Leibbrandt, Andreas ^a   Meier, Christiane ^a   König Schuster, Marielle ^a   Weinmüllner, Regina ^a   Kalthoff, Donata ^b   Pflugfelder, Bettina ^a   Graf, Philipp ^a   Frank Gehrke, Britta ^a   Beer, Martin ^b   Fazekas, Tamas ^c   Unger, Hermann ^d   Prieschl Grassauer, Eva ^a   Grassauer, Andreas ^a  

^a Marinomed Biotechnologie GmbH   (Austria)

^b FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

^c ST ANNA CHILDREN S HOSPITAL   (Austria)

^d UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CARRAGEENAN; OSELTAMIVIR; PLACEBO; ANTIVIRUS AGENT; ENZYME INHIBITOR; POLYMER; POLYSACCHARIDE; SIALIDASE;

2009 H1N1 INFLUENZA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFECTION PREVENTION; INFLUENZA VIRUS A H1N1; LETHAL DOSE; MONOTHERAPY; MOUSE; NONHUMAN; PANDEMIC INFLUENZA; SURVIVAL RATE; VIRUS INHIBITION; ANIMAL; ANTIVIRAL RESISTANCE; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; DOG; DRUG ANTAGONISM; DRUG EFFECT; INFLUENZA; INFLUENZA VIRUS A; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

INFLUENZA A VIRUS; MUS;

ANIMALS; ANTIVIRAL AGENTS; CARRAGEENAN; DISEASE MODELS, ANIMAL; DOGS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, INBRED C57BL; NEURAMINIDASE; OSELTAMIVIR; POLYMERS; POLYSACCHARIDES;

EID: 78650773476     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014320     Document Type: Article

References (61)

1. Hayden F (2009) Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 48: 3-13.
2. Pinto LH, Holsinger LJ, Lamb RA (1992) Influenza virus M2 protein has ion channel activity. Cell 69: 517-528.
3. Schnell JR, Chou JJ (2008) Structure and mechanism of the M2 proton channel of influenza A virus. Nature 451: 591-595.
4. Jefferson T, Demicheli V, Di Pietrantonj C, Rivetti D (2006) Cochrane-Amantadine and rimantadine for influenza A in adults. Cochrane Database Syst Rev.
5. Nelson MI, Simonsen L, Viboud C, Miller MA, Holmes EC (2009) The origin and global emergence of adamantane resistant A/H3N2 influenza viruses. Virology 388: 270-278.
6. Deyde VM, Xu X, Bright RA, Shaw M, Smith CB, et al. (2007) Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 196: 249-257.
7. Hersh AL, Maselli JH, Cabana MD (2009) Changes in prescribing of antiviral medications for influenza associated with new treatment guidelines. Am J Public Health 99(Suppl 2): S362-S364.
8. von IM(2007) The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov 6: 967-974.
9. Wagner R, Matrosovich M, Klenk HD (2002) Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev Med Virol 12: 159-166.
10. Bantia S, Parker CD, Ananth SL, Horn LL, Andries K, et al. (2001) Comparison of the Anti-Influenza Virus Activity of RWJ-270201 with Those of Oseltamivir and Zanamivir. Antimicrobial agents and chemotherapy 45: 1162-1167.
11. Sidwell RW, Huffman JH, Barnard DL, Bailey KW, Wong MH, et al. (1998) Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res 37: 107-120.
12. Sidwell RW, Smee DF (2000) In vitro and in vivo assay systems for study of influenza virus inhibitors. Antiviral Res 48: 1-16.
13. Jefferson T, Jones M, Doshi P, Del Mar C (2009) Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and metaanalysis. BMJ 339: b5106.
14. Matheson NJ, Harnden AR, Perera R, Sheikh A, Symmonds-Abrahams M (2007) Cochrane-Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev.
15. Shun-Shin M, Thompson M, Heneghan C, Perera R, Harnden A, et al. (2009) Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials. BMJ 339: b3172.
16. Hayden FG, Pavia AT (2006) Antiviral management of seasonal and pandemic influenza. J Infect Dis 194: S119-S126.
17. Khazeni N, Bravata DM, Holty JE, Uyeki TM, Stave CD, et al. (2009) Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza. Ann Intern Med 151: 464-473.
18. Neumann G, Noda T, Kawaoka Y (2009) Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459: 931-939.
19. Palese P (2004) Influenza: old and new threats. Nat Med 10: S82-S87.
20. Baz M, Abed Y, Papenburg J, Bouhy X, Hamelin ME, et al. (2009) Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N Engl J Med 361: 2296-2297.
21. Michel G, Nyval-Collen P, Barbeyron T, Czjzek M, Helbert W (2006) Bioconversion of red seaweed galactans: a focus on bacterial agarases and carrageenases. Appl Microbiol Biotechnol 71: 23-33.
22. Cohen SM, Ito N (2002) A Critical Review of the Toxicological Effects of Carrageenan and Processed Eucheuma Seaweed on the Gastrointestinal Tract. Critical Reviews in Toxicology 32: 413-444.
23. Benford DJ (2008) CARRAGEENAN AND PROCESSED EUCHEUMA SEAWEED (addendum). WHO Food Additives Series 59: 65-82.
24. Turville SG (2008) Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activity. PLoS One 3: e3162.
25. Kilmarx PH, Blanchard K, Chaikummao S, Friedland BA, Srivirojana N, et al. (2008) A randomized, placebo-controlled trial to assess the safety and acceptability of use of carraguard vaginal gel by heterosexual couples in Thailand. Sex Transm Dis 35: 226-232.
26. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, et al. (2008) Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372: 1977-1987.
27. Baba M, Snoeck R, Pauwels R, de Clercq E (1988) Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob Agents Chemother 32: 1742-1745.
28. Gonzalez ME, Alarcon B, Carrasco L (1987) Polysaccharides as antiviral agents: antiviral activity of carrageenan. Antimicrob Agents Chemother 31: 1388-1393.
29. Damonte EB, Matulewicz MC, Cerezo AS (2004) Sulfated seaweed polysaccharides as antiviral agents. Curr Med Chem 11: 2399-2419.
30. Ghosh T, Chattopadhyay K, Marschall M, Karmakar P, Mandal P, et al. (2009) Focus on antivirally active sulfated polysaccharides: from structure-activity analysis to clinical evaluation. Glycobiology 19: 2-15.
31. Witvrouw M, De Clercq E (1997) Sulfated polysaccharides extracted from sea algae as potential antiviral drugs. Gen Pharmacol 29: 497-511.
32. Carlucci MJ, Scolaro LA, Noseda MD, Cerezo AS, Damonte EB (2004) Protective effect of a natural carrageenan on genital herpes simplex virus infection in mice. Antiviral Res 64: 137-141.
33. Hamasuna R, Eizuru Y, Minamishima Y (1994) Inhibition by iota-carrageenan of the spread of murine cytomegalovirus from the peritoneal cavity to the blood plasma. J Gen Virol 75(Pt 1): 111-116.
34. Pujol CA, Scolaro LA, Ciancia M, Matulewicz MC, Cerezo AS, et al. (2006) Antiviral activity of a carrageenan from Gigartina skottsbergii against intraperitoneal murine herpes simplex virus infection. Planta Med 72: 121-125.
35. Carlucci MJ, Ciancia M, Matulewicz MC, Cerezo AS, Damonte EB (1999) Antiherpetic activity and mode of action of natural carrageenans of diverse structural types. Antiviral Res 43: 93-102.
36. Talarico LB, Damonte EB (2007) Interference in dengue virus adsorption and uncoating by carrageenans. Virology 363: 473-485.
37. Girond S, Crance JM, Van Cuyck-Gandre H, Renaudet J, Deloince R (1991) Antiviral activity of carrageenan on hepatitis A virus replication in cell culture. Res Virol 142: 261-270.
38. Buck CB, Thompson CD, Roberts JN, Muller M, Lowy DR, et al. (2006) Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog 2: e69.
39. Perez-Andino J, Buck CB, Ribbeck K (2009) Adsorption of human papillomavirus 16 to live human sperm. PLoS One 4: e5847.
40. Grassauer A, Weinmuellner R, Meier C, Pretsch A, Prieschl-Grassauer E, et al. (2008) Iota-Carrageenan is a potent inhibitor of rhinovirus infection. Virol J 5.
41. Hayden FG, Cote KM, Douglas RG Jr. (1980) Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob Agents Chemother 17: 865-870.
42. Barnard DL (2009) Animal models for the study of influenza pathogenesis and therapy. Antiviral Res 82: A110-A122.
43. Diaz MO, Ziemin S, Le Beau MM, Pitha P, Smith SD, et al. (1988) Homozygous deletion of the alpha-and beta 1-interferon genes in human leukemia and derived cell lines. Proc Natl Acad Sci U S A 85: 5259-5263.
44. Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, et al. (2010) Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 362: 1708-1719.
45. Kalthoff D, Grund C, Harder TC, Lange E, Vahlenkamp TW, et al. (2010) Limited susceptibility of chickens, turkeys, and mice to pandemic (H1N1) 2009 Virus. Emerg Infect Dis 16: 703-705.
46. Burch J, Corbett M, Stock C, Nicholson K, Elliot AJ, et al. (2009) Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis. Lancet Infect Dis 9: 537-545.
47. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, et al. (2008) Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 52: 3284-3292.
48. Stephenson I, Democratis J, Lackenby A, McNally T, Smith J, et al. (2009) Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis 48: 389-396.
49. Poland GA, Jacobson RM, Ovsyannikova IG (2009) Influenza virus resistance to antiviral agents: a plea for rational use. Clin Infect Dis 48: 1254-1256.
50. Herlocher ML, Truscon R, Elias S, Yen HL, Roberts NA, et al. (2004) Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 190: 1627-1630.
51. Ives JA, Carr JA, Mendel DB, Tai CY, Lambkin R, et al. (2002) The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 55: 307-317.
52. Baz M, Abed Y, Simon P, Hamelin ME, Boivin G (2010) Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses. J Infect Dis 201: 740-745.
53. Dharan NJ, Gubareva LV, Meyer JJ, Okomo-Adhiambo M, McClinton RC, et al. (2009) Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 301: 1034-1041.
54. Gooskens J, Jonges M, Claas EC, Meijer A, van den Broek PJ, et al. (2009) Morbidity and mortality associated with nosocomial transmission of oseltamivirresistant influenza A(H1N1) virus. JAMA 301: 1042-1046.
55. Rameix-Welti M-A, Enouf V, Cuvelier F, Jeannin P, van der Werf S (2008) Enzymatic Properties of the Neuraminidase of Seasonal H1N1 Influenza Viruses Provide Insights for the Emergence of Natural Resistance to Oseltamivir. PLoS Pathog 4: e1000103.
56. Moscona A (2009) Global transmission of oseltamivir-resistant influenza. N Engl J Med 360: 953-956.
57. Weinstock DM, Zuccotti G (2009) The evolution of influenza resistance and treatment. JAMA 301: 1066-1069.
58. van de Velde F, Knutsen SH, Usov AI, Rollema HS, Cerezo AS (2002) 1H and 13C high resolution NMR spectroscopy of carrageenans: application in research and industry. Trends in Food Science and Technology 13: 73-92.
59. Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoints. Am J Hyg. pp 493-497.
60. Huang S, Wang H, Carroll CA, Hayes SJ, Weintraub ST, et al. (2004) Analysis of proteins stained by Alexa dyes. Electrophoresis 25: 779-784.
61. Eccles R, Meier C, Jawad M, Weinmüllner R, Grassauer A, et al. (2010) Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, doubleblind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold. Respir Res 11: 108.